February 10, 2023 – Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with ...

Prostate-specific antigen (PSA) testing for prostate cancer may be targeted to men unlikely to benefit from the test, including those age 70 and older, according to a U.K. study. Contrary to ...

Dear Dr. Gott: I'm 68 and had my prostate removed in 1995 because of cancer. Three months after surgery, my PSA level was 0.3. Over the years, it has steadily increased and is now 4.5. What does this ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...

Analysis of the efficacy and tolerance or darolutamide in combination with chemotherapy and ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Spanish population in a ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...